What is AviadoBio?
Founded in 2019 and headquartered in London, UK, AviadoBio is dedicated to developing innovative gene therapies for debilitating neurological diseases. The company's focus on this critical area of unmet medical need positions it as a key player in the rapidly evolving biotechnology sector. The recent enterprise-level funding indicates a strong market belief in AviadoBio's scientific approach and therapeutic pipeline.
How much funding has AviadoBio raised?
AviadoBio has raised a total of $80M across 1 funding round:
Series A
$80M
Series A (2021): $80M with participation from Monograph Capital and New Enterprise Associates
Key Investors in AviadoBio
Monograph Capital
Monograph Capital is an investor in AviadoBio's funding round. Further details on their investment focus are not publicly available.
New Enterprise Associates
New Enterprise Associates (NEA) is a venture capital firm established in 1977, headquartered in Menlo Park, California. NEA focuses on helping entrepreneurs build businesses, particularly in the technology and healthcare sectors.
What's next for AviadoBio?
With the recent influx of capital, AviadoBio is poised for significant expansion and advancement of its gene therapy programs. This strategic investment will likely fuel further research and development, clinical trial progression, and the scaling of its operational capabilities. The company's trajectory suggests a move towards later-stage development and potential commercialization, solidifying its position in the competitive landscape of neurological disease treatment.
See full AviadoBio company page
